

Endoplasmin - Pipeline Review, H2 2019

<https://marketpublishers.com/r/E24C97321228EN.html>

Date: December 2019

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: E24C97321228EN

Abstracts

Endoplasmin - Pipeline Review, H2 2019

SUMMARY

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Endoplasmin - Pipeline Review, H2 2019, outlays comprehensive information on the Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Heat shock protein 90kDa beta member 1 (HSP90B1), known also as endoplasmin. It functions in the processing and transport of secreted proteins and endoplasmic reticulum associated degradation (ERAD). The molecules developed by companies in Phase II, Phase I, Discovery and Unknown stages are 2, 1, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Non-Small Cell Lung Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

Furthermore, this report also reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics development

with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)

The report reviews Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics and enlists all their major and minor projects

The report assesses Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Overview

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Companies Involved in Therapeutics Development

Agenus Inc

Amgen Inc

Heat Biologics Inc

Spectrum Pharmaceuticals Inc

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Drug Profiles
Fusion Protein to Target GRP94 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-130 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panvotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GRP94 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitespen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Dormant Products

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Product Development Milestones

Featured News & Press Releases

Dec 16, 2019: Heat Biologics announces first patient dosed in the first phase 1 trial of HS-130

Aug 12, 2019: Heat Biologics announces FDA clearance of IND application to begin phase 1 trial of HS-130 in combination with Heat's HS-110

Apr 02, 2019: Heat Biologics delivers poster presentation at the AACR Annual Meeting 2019

Jun 01, 2015: Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO

May 14, 2015: Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls

Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis

Jan 21, 2014: Agenus' Prophage Vaccine for Glioma Hailed As a 'Very Promising

Therapy' in an Editorial Published in the Journal Neuro-Oncology

Dec 16, 2013: Positive Phase 2 Results from Agenus' Brain Cancer Vaccine Published in Neuro-Oncology

Sep 17, 2013: Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients

May 22, 2013: Agenus Announces Initiation Of Enrollment In NCI-sponsored Randomized Trial Of Prophage G-200 Vaccine With Avastin In Treatment Of Brain Tumors

May 01, 2013: Agenus Announces Presentation Of Preliminary Data From Phase II Clinical Trial Of Brain Cancer Vaccine At AANS Meeting

Apr 10, 2013: Agenus Presents Brain Cancer Vaccine Results At 81st AANS Annual Scientific Meeting 2013

Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research

Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of AANS

Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Heat Biologics Inc, H2 2019
Pipeline by Spectrum Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Agenus Inc

Amgen Inc

Heat Biologics Inc

Spectrum Pharmaceuticals Inc

I would like to order

Product name: Endoplasmin - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/E24C97321228EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E24C97321228EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970